Clinical Trial Update: Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating tislelizumab plus zeprumetostat for relapsed or refractory NK/T-cell lymphoma is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma
• Nk T-cell Lymphoma
• Or Refractory Nk T-cell Lymphoma

Drugs mentioned

• Tislelizumab (tislelizumab)
• Zeprumetostat (zeprumetostat)

Snippet

Sponsor: Rong Tao | Conditions: Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING